Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994213 | 0.92 | PPARG (0.52) | PPARGALDH1A1CYP3A4RAB9ALMNA | |
| SCHEMBL1997355 | 0.85 | KMT2A (0.56) | PPARGALDH1A1CYP3A4RAB9ALMNA | |
| SCHEMBL3802331 | 0.85 | ALDH1A1 (0.62) | PPARGALDH1A1CYP3A4RAB9ALMNA | |
| SCHEMBL2000056 | 0.84 | MAPT (0.45) | PPARGALDH1A1CYP3A4RAB9ALMNA | |
| SCHEMBL29612551 | 0.84 | PPARG (0.53) | PPARGALDH1A1CYP3A4RAB9ALMNA | |
| SCHEMBL28730677 | 0.84 | PPARG (0.53) | PPARGALDH1A1CYP3A4RAB9ALMNA | |
| SCHEMBL2001900 | 0.81 | CHEK2 (0.43) | PPARGCYP3A4HTTPIN1MEN1 | |
| SCHEMBL11291316 | 0.81 | PIN1 (0.51) | PPARGALDH1A1LMNAHTTPIN1 | |
| SCHEMBL22515313 | 0.81 | PPARG (0.62) | PPARGALDH1A1CYP3A4HTT | |
| SCHEMBL633564 | 0.80 | PPARG (0.58) | PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | LANFEAR DENNIS (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | LANFEAR DENNIS (US) | 2013-09-19 | — | — | US | disclosed |
| EP-1677797-B1 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-1677797-B1 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8003665-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003665-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003665-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1677797-A4 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2007-12-20 | — | — | US | disclosed |
| US-7223761-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223761-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223761-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1677797-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | Amgen Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2005033074-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | PPARD, PPARA, PPARG | PPARG 3/4885ALDH1A1 1212/4885CYP3A4 539/4885 |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | PPARD, PPARA, PPARG | PPARG 3/4885ALDH1A1 1212/4885CYP3A4 539/4885 |
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | PPARG 8/4885ALDH1A1 1239/4885CYP3A4 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.